**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 48829**

**Manuscript type: LETTER TO THE EDITOR**

**Letter to the editor: Diagnosis of erythropoietic protoporphyria with severe liver injury - a case report**

WensinkD *et al*. Severe liver injury in erythropoietic protoporphyria

Debby Wensink, Margreet AEM Wagenmakers, JH Paul Wilson, Janneke G Langendonk

**Debby Wensink, Margreet AEM Wagenmakers, JH Paul Wilson, Janneke G Langendonk,** Porphyria Center Rotterdam, Center for lysosomal and metabolic disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam 3015 GD , Netherlands

**ORCID number:** Debby Wensink (0000-0002-7249-5810); Margreet AEM Wagenmakers (0000-0003-2587-0283); JH Paul Wilson (0000-0001-6995-7044); Janneke G Langendonk (0000-0002-4899-7239).

**Author contributions:** Wensink D drafted the manuscript; Langendonk JG, Wagenmakers MAEM and Wilson JH edited and revised the manuscript. Wensink D approved the final version of the manuscript.

**Conflict-of-interest statement:** Langendonk JG reports grants from Clinuvel and Alnylam, outside the submitted work. All other authors declared no conflict-of-interest.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Janneke G Langendonk, MD, PhD, Doctor,** Department of Internal Medicine, Erasmus Medical Center, Dr. Molenwaterplein 40, Rotterdam 3015 GD, Netherlands. j.langendonk@erasmusmc.nl

**Telephone:** +31-10-7035191

**Fax:** +31-10-7033639

**Received:** May 7, 2019

**Peer-review started:** May 7, 2019

**First decision:** June 9, 2019

**Revised:** July 17, 2019

**Accepted:** July 19, 2019

**Article in press:** July 19, 2019

**Published online:** August 14, 2019

**Abstract**

Erythropoietic protoporphyria (EPP) is an extremely rare disease which is often unrecognized as diagnosis. In the recent article of Lui et al they describe a case report with a new diagnose of EPP with severe liver injury. Approximately 5%-20% of patients with EPP develop liver manifestations. The most severe complication of EPP is hepatic crisis, which is an medical urgency requiring urgent treatment. Intensive treatment should consist of (exchange) transfusions and preferably in a center that performs liver transplantations.

**Key words:**Erythropoietic protoporphyria; Liver disease; Blood transfusion; Protoporphyrin IX; Treatment

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Erythropoietic protoporphyria (EPP) can be complicated with severe liver injury. The major highlight of this letter is to stress that an EPP hepatic crisis has to be recognized as it can be fatal, and the best therapeutic options are (exchange) transfusions and preferably in a center that performs liver transplantations.

Wensink D, Wagenmakers MAEM, Wilson JH, Langendonk JG. Letter to the editor: Diagnosis of erythropoietic protoporphyria with severe liver injury - a case report. *World J Gastroenterol* 2019; 25(30): 4292-4293

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i30/4292.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i30.4292

**TO THE EDITOR**

With great interest we read the case report on the diagnosis of erythropoietic protoporphyria (EPP) with severe liver injury by Liu *et al*[1] in the February 2019 issue of *World Journal of Gastroenterology*. They report a case presenting with weight loss, jaundice, and hepatitis. After extensive investigation the diagnosis of EPP was made and the liver disease was explained as related to EPP. We greatly appreciate the dedication of the authors to improve awareness of EPP and EPP related liver injury in order to aid early recognition.

In addition to their paper, we like to propose treatment options for severely ill patients. Approximately 5%-20% of patients with EPP develop liver manifestations[2]. Hepatic manifestations of the disease are diverse, ranging from mildly disturbed liver enzymes, choledocholithiases at early age to fatal hepatic failure. The case of Liu et al reports elevated transaminases, hyperbilirubinemia, enlargement of the liver and ascites on magnetic resonance imaging (MRI) suggesting severe liver disease. The most severe complication of EPP, which can rapidly result in fatal hepatic failure, is cholestatic liver failure, which we, by analogy with the hepatic crises of sickle cell disease, designate as an EPP hepatic crisis, to accentuate that this condition is a medical emergency requiring urgent treatment. These EPP crises present with severe abdominal pain, jaundice, and biochemically severe cholestatic hepatitis, accompanied by a significant increase in erythrocyte and plasma protoporphyrin IX over preexisting levels. During a hepatic crisis, which is often luxated when the liver is damaged by another cause such as alcohol consumption or viral hepatitis, the biliary excretion of protoporphyrin is reduced, leading to a rise of protoporphyrin levels which may further damage the canaliculi and biliary tract. This results in a vicious circle causing further liver damage and rapidly leads to acute liver failure if left untreated. In case of a hepatic crisis the suggested treatment of Liu et al, consisting of avoiding light, drinking glucose water, and a carrot diet, including β carotene resulted in recovery of their patient. We suggest a more intensive treatment in severely ill patients to prevent possible fatal outcome. The cornerstone of this therapy is to quickly lower protoporphyrin levels in order to provide an opportunity for the liver to recover. This can be achieved with exchange transfusions[3]. In addition, suppression of hematopoiesis and endogenous protoporphyrin production via blood transfusions to supraphysiological hemoglobin levels should be considered[4]. If this treatment fails, liver transplantation is the only treatment option left[5]. Because of the severity of EPP-related liver crises, prevention of liver damage should be attempted in all EPP patients, by advising against and restricting alcohol consumption, avoiding potentially hepatotoxic drugs and vaccinating against hepatitis A and B virus[6].

To conclude, a severe EPP hepatic crisis can be fatal and should be treated intensively *via* (exchange) transfusions and preferably in a center that performs liver transplantations.

**REFERENCES**

1 **Liu HM**, Deng GH, Mao Q, Wang XH. Diagnosis of erythropoietic protoporphyria with severe liver injury: A case report. *World J Gastroenterol* 2019; **25**: 880-887 [PMID: 30809087 DOI: 10.3748/wjg.v25.i7.880]

2 **Casanova-González MJ**, Trapero-Marugán M, Jones EA, Moreno-Otero R. Liver disease and erythropoietic protoporphyria: a concise review. *World J Gastroenterol* 2010; **16**: 4526-4531 [PMID: 20857522 DOI: 10.3748/wjg.v16.i36.4526]

3 **Anstey AV**, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. *Gut* 2007; **56**: 1009-1018 [PMID: 17360790]

4 **Dobozy A**, Csató M, Siklósi C, Simon N. Transfusion therapy for erythropoietic protoporphyria. *Br J Dermatol* 1983; **109**: 571-576 [PMID: 6639879 DOI: 10.1111/j.1365-2133.1983.tb07681.x]

5 **Wahlin S**, Stal P, Adam R, Karam V, Porte R, Seehofer D, Gunson BK, Hillingsø J, Klempnauer JL, Schmidt J, Alexander G, O'Grady J, Clavien PA, Salizzoni M, Paul A, Rolles K, Ericzon BG, Harper P; European Liver and Intestine Transplant Association. Liver transplantation for erythropoietic protoporphyria in Europe. *Liver Transpl* 2011; **17**: 1021-1026 [PMID: 21604355 DOI: 10.1002/lt.22341]

6 **Bonkovsky HL**, Schned AR. Fatal liver failure in protoporphyria. Synergism between ethanol excess and the genetic defect. *Gastroenterology* 1986; **90**: 191-201 [PMID: 3940245 DOI: 10.1016/0016-5085(86)90093-4]

**P-Reviewer:** Ma XC, Tarantino G

**S-Editor:** Ma RY **L-Editor:** **A E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Netherlands

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0